Robert C. Malenka - 27 Oct 2025 Form 4 Insider Report for MapLight Therapeutics, Inc. (MPLT)

Role: Director
Signature: /s/ Kristopher L. Hanson, Attorney-in-Fact
Issuer symbol: MPLT
Transactions as of: 27 Oct 2025
Net transactions value: $0
Form type: 4
Filing time: 28 Oct 2025, 16:15:11 UTC
Previous filing: 27 Oct 2025
Next filing: 30 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Malenka Robert C.	Director	C/O MAPLIGHT THERAPEUTICS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY	/s/ Kristopher L. Hanson, Attorney-in-Fact	28 Oct 2025	0002021198

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MPLT	Voting Common Stock	Award	$0	+34,390	+9.4%	$0.000000	399,671	27 Oct 2025	Direct	F1, F2
transaction	MPLT	Voting Common Stock	Conversion of derivative security		+3,895	+14%		31,672	28 Oct 2025	See footnote	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MPLT	Employee Stock Option (right to buy)	Award	$0	+139,610		$0.000000	139,610	27 Oct 2025	Voting Common Stock	139,610	$17.00	Direct	F5
transaction	MPLT	Series C Preferred Stock	Conversion of derivative security	$0	-65,477	-100%	$0.000000	0	28 Oct 2025	Voting Common Stock	3,895		See footnote	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. 25% of the RSUs shall vest on October 1, 2026, and 1/16th of the RSUs shall vest on each subsequent January 1, April 1, July 1 and October 1 thereafter, subject to the Reporting Person's continued service through each vesting date.
F2	Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
F3	The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
F4	The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.
F5	1/4th of the total shares underlying the option shall vest on October 1, 2026, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.